David A. Siegel Exelixis, Inc. Transaction History

Two Sigma Advisers, LP

$42.5 Billion
Q1 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Exelixis, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 1,755,890 shares of EXEL stock, worth $39.5 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

1,755,890

Previous 1,840,490 4.6%

Holding current value

$39.5 Million

Previous $44.2 Million 5.63%

% of portfolio

0.1%

Previous 0.1%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $1.71 Million - $2.02 Million	-84,600 Reduced 4.6%	1,755,890 $41.7 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $7.19 Million - $9.02 Million	-373,700 Reduced 16.88%	1,840,490 $44.2 Million
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $1.6 Million - $1.91 Million	-83,800 Reduced 3.65%	2,214,190 $48.4 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $11.4 Million - $12.8 Million	626,600 Added 37.49%	2,297,990 $43.9 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $9.13 Million - $10.9 Million	560,300 Added 50.43%	1,671,390 $32.4 Million

Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $40,392 - $46,953	2,700 Added 0.24%	1,111,090 $17.8 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $11.2 Million - $16 Million	-716,500 Reduced 39.26%	1,108,390 $17.4 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $3.82 Million - $5.07 Million	-219,100 Reduced 10.72%	1,824,890 $38 Million
Q1 2022 May 16, 2022	SELL	$17.03 - $22.67 $4.32 Million - $5.75 Million	-253,600 Reduced 11.04%	2,043,990 $46.3 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $1.28 Million - $1.77 Million	81,100 Added 3.66%	2,297,590 $42 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $15.5 Million - $20.1 Million	952,900 Added 75.41%	2,216,490 $46.9 Million
Q2 2021 Aug 16, 2021	BUY	$17.95 - $25.56 $11.3 Million - $16.1 Million	629,400 Added 99.24%	1,263,590 $23 Million
Q1 2021 May 17, 2021	BUY	$20.53 - $25.22 $3.15 Million - $3.86 Million	153,200 Added 31.85%	634,190 $14.3 Million
Q4 2020 Feb 16, 2021	BUY	$18.39 - $24.8 $23,907 - $32,240	1,300 Added 0.27%	480,990 $9.65 Million
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $10.5 Million - $13.7 Million	-507,500 Reduced 51.41%	479,690 $11.7 Million
Q2 2020 Aug 14, 2020	BUY	$16.46 - $27.42 $14.6 Million - $24.3 Million	887,855 Added 893.8%	987,190 $23.4 Million
Q1 2020 May 15, 2020	SELL	$14.46 - $21.8 $2.66 Million - $4.02 Million	-184,300 Reduced 64.98%	99,335 $1.71 Million
Q4 2019 Feb 14, 2020	SELL	$15.15 - $18.89 $5.93 Million - $7.39 Million	-391,200 Reduced 57.97%	283,635 $5 Million
Q3 2019 Nov 14, 2019	BUY	$17.68 - $22.65 $3.31 Million - $4.24 Million	187,300 Added 38.42%	674,835 $11.9 Million
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $9.23 Million - $12.1 Million	487,535 New	487,535 $10.4 Million
Q1 2019 May 15, 2019	SELL	$19.6 - $24.76 $227,967 - $287,983	-11,631 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$13.65 - $21.8 $158,763 - $253,555	11,631 New	11,631 $229,000
Q3 2018 Nov 14, 2018	SELL	$15.87 - $22.4 $17.2 Million - $24.2 Million	-1,081,321 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$18.56 - $22.45 $11.6 Million - $14 Million	-624,400 Reduced 36.61%	1,081,321 $23.3 Million
Q1 2018 May 15, 2018	SELL	$22.15 - $31.89 $41.6 Million - $59.9 Million	-1,876,800 Reduced 52.39%	1,705,721 $37.8 Million
Q4 2017 Feb 14, 2018	SELL	$24.23 - $30.93 $13.7 Million - $17.5 Million	-566,817 Reduced 13.66%	3,582,521 $109 Million
Q3 2017 Nov 14, 2017	BUY	$23.35 - $29.24 $96.9 Million - $121 Million	4,149,338	4,149,338 $101 Million

Others Institutions Holding EXEL

# of Institutions

459

Shares Held

246M

Call Options Held

1.7M

Put Options Held

1.02M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.23B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account